Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
17.79
-0.35 (-1.93%)
At close: Oct 14, 2025, 4:00 PM EDT
18.00
+0.21 (1.18%)
After-hours: Oct 14, 2025, 7:18 PM EDT
Mesoblast Revenue
In the fiscal year ending June 30, 2025, Mesoblast had annual revenue of $17.20M with 191.39% growth. Mesoblast had revenue of $14.04M in the half year ending June 30, 2025, with 244.25% growth.
Revenue (ttm)
$17.20M
Revenue Growth
+191.39%
P/S Ratio
133.15
Revenue / Employee
$212,321
Employees
81
Market Cap
2.29B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 17.20M | 11.30M | 191.39% |
Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
MESO News
- 8 days ago - Ryoncil® Revenues Increase 66% in Second Quarter Post Launch - GlobeNewsWire
- 8 days ago - Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 12 days ago - Ryoncil® Receives J-Code From Medicare & Medicaid Services (CMS) Facilitating Reimbursement and Broader Patient Access - GlobeNewsWire
- 19 days ago - Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs - GlobeNewsWire
- 4 weeks ago - Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences - GlobeNewsWire
- 5 weeks ago - Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - GlobeNewsWire
- 6 weeks ago - Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil® - GlobeNewsWire